Pancreatic cancer is one of the deadliest of cancers with an average survival rate of 6-8 months and 5-year survival of max 5-6%. The goal now is to define a diagnostic / predictive and stratifying tissue marker panel in pancreatic cancer. This in order to improve and design a more tailor-made treatment and define subgroups that better respond to different types of therapy.